Associated Papers
Incidence and impact of non-canonical JAK2 p.(Val617Phe) mutations in myeloproliferative neoplasm molecular diagnostics.
Patchell D et al.
Journal of Clinical Pathology, 2025
Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.
Verma T et al.
Cancers, 2024
Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms.
Morishita S et al.
International Journal of Molecular Sciences, 2023
37629188 (PubMed )
Supplement: ijms-24-13008-s001.zip › ijms-2555672-supplementary.pdf
Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls.
Maslah N et al.
Annals of Hematology, 2019
Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis.
Lippert E et al.
Haematologica, 2014
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Tefferi A
Journal of Cellular and Molecular Medicine, 2009
Select a paper to view details